Events

The COVID-19 crisis has spurred tremendous public and private innovation efforts, particularly in the area of vaccines. Although the social benefits of one or more safe and effective vaccines are undeniable, analysts are concerned that a vaccine authorized by the FDA through emergency use authorization (EUA) may not be both safe and effective. Additionally, in the area of vaccines, public trust plays a large role in determining ultimate social benefit. So the effect of EUA on public trust in COVID-19 vaccine innovation, and in the FDA more generally, merit close attention.

The Center for Innovation Policy at Duke Law (CIP), together with Duke Science & Society and other co-sponsors, hosted a discussion of the suitability of the EUA process for COVID vaccine innovation

Panelists:

• Robert Califf, former FDA Commissioner
• Eric Topol, Founder and Director of the Scripps Research Translational Institute

Moderator:

• Arti Rai, CIP Director and Elvin R. Latty Professor

Watch The Recording